"Zalicus Stock is starting to look very interesting at this level. Traders are no doubt waiting for the two big Phase 2 trials to offer data on potential blockbuster drug Z160 coming in late October 2013. But now might be the time value biotech investors take a look at the stock. The current market capitalization is only $65 million. That's only 4x our projected 2013 revenues of $16.0 million, and nearly one-third of the market capitalization is supported by the cash balance.
With Z160 a potential blockbuster and the top-line supporting the stock at today's price, Zalicus could be poised for a big second half of the year."